Skip to main content
. 2014 Jan 17;62(1):111–116. doi: 10.1111/jgs.12595

Figure 2.

Figure 2

Cost-effectiveness acceptability curves, for high-urinary tract infection (UTI)-risk participants (the probability that cranberry use is more cost-effective than placebo, depending on how much one is willing to pay for a quality-adjusted life year (QALY), based on utility measured using the EQ-5D or the visual analog scale (VAS)).